Project title: Next generation animal models to define therapies for NETs

Pawel Mazur, PhD MD Anderson Cancer Center

Pawel Mazur, PhD

General Description

Mazur will explore an enzyme (KMT NSD3 or NSD3) in laboratory models of pNETs with genomic alterations in PTEN, MEN1, and ATRX to see if it helps pancreatic NETs. NSD3 may amplify the impact of these alterations, helping to give neuroendocrine cancer cells the “green light” to reproduce and grow.  

NETRF Awards Six Grants

NETRF awarded six new research grants totaling $1.85 million to leading academic institutions around the world. The goal of the funding is to improve current treatments for neuroendocrine tumors (NETs), an uncommon and poorly understood cancer, which occurs in the body’s hormone-producing cells.


We have developed a mouse model of pancreatic neuroendocrine tumors. We found that NSD3 methyltransferase is important driver of malignant progression. We concluded that targeting NSD3 could be beneficial in treatment of pancreatic neuroendocrine tumors.

Additional Details

  • City: Houston
  • State: Texas
  • Grant Duration: 2 years
  • Grant Partner: American Association for Cancer Research (AACR)
  • Awards: No information


NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.

« Back to all funded research projects